SG11201404921QA - Method for treating gynecological diseases - Google Patents

Method for treating gynecological diseases

Info

Publication number
SG11201404921QA
SG11201404921QA SG11201404921QA SG11201404921QA SG11201404921QA SG 11201404921Q A SG11201404921Q A SG 11201404921QA SG 11201404921Q A SG11201404921Q A SG 11201404921QA SG 11201404921Q A SG11201404921Q A SG 11201404921QA SG 11201404921Q A SG11201404921Q A SG 11201404921QA
Authority
SG
Singapore
Prior art keywords
gynecological diseases
treating gynecological
treating
diseases
gynecological
Prior art date
Application number
SG11201404921QA
Other languages
English (en)
Inventor
Jean-Pierre Gotteland
Valérie Boujac
Ernest Loumaye
Original Assignee
Preglem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Preglem Sa filed Critical Preglem Sa
Publication of SG11201404921QA publication Critical patent/SG11201404921QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11201404921QA 2012-03-23 2013-03-22 Method for treating gynecological diseases SG11201404921QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614785P 2012-03-23 2012-03-23
EP12160956.4A EP2641602A1 (de) 2012-03-23 2012-03-23 Verfahren zur Behandlung gynäkologischer Leiden
PCT/IB2013/052274 WO2013140372A1 (en) 2012-03-23 2013-03-22 Method for treating gynecological diseases

Publications (1)

Publication Number Publication Date
SG11201404921QA true SG11201404921QA (en) 2014-10-30

Family

ID=45976689

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201404921QA SG11201404921QA (en) 2012-03-23 2013-03-22 Method for treating gynecological diseases

Country Status (18)

Country Link
US (1) US10441534B2 (de)
EP (3) EP2641602A1 (de)
JP (2) JP2015514700A (de)
KR (1) KR20140138824A (de)
CN (1) CN104203246A (de)
AU (1) AU2013236960B2 (de)
CA (1) CA2864073A1 (de)
CO (1) CO7111317A2 (de)
EA (1) EA031488B1 (de)
GE (1) GEP201706696B (de)
HK (1) HK1199827A1 (de)
MX (1) MX369520B (de)
MY (1) MY172530A (de)
NZ (1) NZ630011A (de)
SG (1) SG11201404921QA (de)
TW (2) TW201832767A (de)
WO (1) WO2013140372A1 (de)
ZA (1) ZA201407575B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6906525B2 (ja) 2015-12-23 2021-07-21 オリック ファーマシューティカルズ，インク． グルココルチコイド受容体の阻害剤
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CA3009525A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017165707A1 (en) * 2016-03-24 2017-09-28 Juniper Pharmaceuticals, Inc. Vaginal administration of agents for treating and preventing pain associated with gynecological medical procedures
MX2019004030A (es) 2016-10-07 2019-09-16 Oric Pharmaceuticals Inc Inhibidores del receptor de glucocorticoides.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3920805A (en) 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
IL48277A (en) 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US4155991A (en) 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
US3995633A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US3991760A (en) 1975-12-02 1976-11-16 The Procter & Gamble Company Vaginal medicament dispensing means
US3995634A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal cavity dispensing means and method
US4286587A (en) 1978-10-11 1981-09-01 Alza Corporation Vaginal drug delivery system made from polymer
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US4250611A (en) 1979-04-19 1981-02-17 Alza Corporation Process for making drug delivery device with reservoir
US4596576A (en) 1984-10-12 1986-06-24 Akzo N.V. Release system for two or more active substances
NL8500470A (nl) 1985-02-19 1986-09-16 Achel Homesteel Pvba Intravaginaal orgaan.
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FI95768C (fi) 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
EP1613640A4 (de) 2003-02-28 2010-05-19 Us Gov Health & Human Serv Verfahren zur herstellung von 17 alpha-acetoxy-11 beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dion, zwischenprodukte dafür, und verfahren zur herstellung dieser zwischenprodukte
WO2006010097A2 (en) 2004-07-09 2006-01-26 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
WO2008129396A2 (en) * 2007-04-20 2008-10-30 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
CA2713943C (en) * 2008-02-04 2018-10-23 Teva Women's Health, Inc. Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof

Also Published As

Publication number Publication date
GEP201706696B (en) 2017-07-10
CN104203246A (zh) 2014-12-10
US20150038476A1 (en) 2015-02-05
CA2864073A1 (en) 2013-09-26
EP3363500A1 (de) 2018-08-22
HK1199827A1 (en) 2015-07-24
NZ630011A (en) 2016-12-23
MX2014011487A (es) 2015-01-12
CO7111317A2 (es) 2014-11-10
EA031488B1 (ru) 2019-01-31
WO2013140372A1 (en) 2013-09-26
EP2827873A1 (de) 2015-01-28
AU2013236960A1 (en) 2014-09-25
JP2018109025A (ja) 2018-07-12
TW201400121A (zh) 2014-01-01
MX369520B (es) 2019-11-11
EP2641602A1 (de) 2013-09-25
AU2013236960B2 (en) 2017-11-23
EA201491614A1 (ru) 2015-01-30
ZA201407575B (en) 2015-12-23
MY172530A (en) 2019-11-29
TW201832767A (zh) 2018-09-16
KR20140138824A (ko) 2014-12-04
US10441534B2 (en) 2019-10-15
JP2015514700A (ja) 2015-05-21

Similar Documents

Publication Publication Date Title
HK1212972A1 (zh) 作爲 -蛋白抑制劑用於治療過度增殖性疾病的吡咯並-和吡唑並-三唑並二氮雜卓
HUE062051T2 (hu) Eljárás sajtolva keményített acél darabok gyártására
EP2611765A4 (de) Verfahren zur behandlung neurodegenerativer erkrankungen
DK3292875T3 (en) Compositions and methods for treating diseases
ZA201208219B (en) Method for treating wasterwater
HK1215173A1 (zh) 治療金黃色葡萄球菌相關疾病的方法
HK1204452A1 (en) Treatment for bone diseases
HK1203370A1 (en) Method for treatment of labor arrest
HK1216504A1 (zh) 疾病的治療方法
HK1199827A1 (en) Method for treating gynecological diseases
EP2816126A4 (de) Wärmebehandlungsverfahren
EP2854784A4 (de) Verfahren zur behandlung von hautentzündungserkrankungen
EP2849778A4 (de) Verfahren zur behandlung einer entzündung
PL2809760T3 (pl) Sposób zmniejszania przykrych zapachów
PL2882432T3 (pl) Sposób leczenia trądziku
GB201121950D0 (en) Treatment process
HK1209040A1 (en) Methods for treating vestibulotoxicity
ZA201407215B (en) Method for emulsion treatment
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
GB201105523D0 (en) Treatment method
PL2730177T3 (pl) Sposób obróbki jaj
EP2813798A4 (de) Sprengbearbeitungsverfahren
EP2854774A4 (de) Verfahren zur behandlung von schlaflosigkeit
GB201205449D0 (en) Treatment process
GB201217173D0 (en) Therapeutic method